What is NAFLD?
Non-alcoholic fatty liver disease (NAFLD) is the accumulation of excess fat in liver cells in people who drink little or no alcohol. It is a spectrum condition ranging from simple steatosis (fat accumulation without inflammation) to non-alcoholic steatohepatitis (NASH, which includes inflammation and cell damage), and in some cases to fibrosis, cirrhosis, and liver failure.
NAFLD affects approximately 25% of the global adult population and is now the most common cause of chronic liver disease in developed countries. It occurs across all age groups, including children, but is most prevalent in adults with obesity, type 2 diabetes, and metabolic syndrome.
In 2023, the condition was formally renamed metabolic dysfunction-associated steatotic liver disease (MASLD) to better reflect its metabolic origins, though the term NAFLD remains widely used.
Signs and symptoms
NAFLD is usually asymptomatic in its early stages and is often discovered incidentally on bloodwork or imaging done for another reason. When symptoms do occur:
What causes NAFLD?
The primary driver is insulin resistance, which causes the liver to accumulate fat from multiple sources: increased free fatty acid delivery from adipose tissue, increased liver fat synthesis, and reduced fat export. Key risk factors include:
- Obesity — particularly central (abdominal) obesity; present in the majority of NAFLD cases
- Type 2 diabetes and insulin resistance — strongly associated; NAFLD and diabetes often co-occur
- High triglycerides and low HDL cholesterol — components of metabolic syndrome
- Rapid weight loss — paradoxically can worsen NASH by mobilizing large amounts of fat
- Certain medications — corticosteroids, some HIV antiretrovirals, amiodarone, and others
- Genetics — variants in the PNPLA3, TM6SF2, and MBOAT7 genes increase susceptibility
A sustained weight loss of 7–10% of body weight can reduce liver fat by 40% or more and, in many cases, resolve the inflammation of NASH.
Can NAFLD be managed online?
Telehealth is appropriate for evaluation, metabolic management, and monitoring of NAFLD, particularly when the metabolic drivers (weight, blood sugar, lipids) are being addressed. The initial diagnosis typically requires liver function tests and imaging (ultrasound) — the clinician can order labs and coordinate referrals for imaging.
Advanced disease (cirrhosis or suspected NASH with significant fibrosis) requires in-person gastroenterology or hepatology involvement, as liver biopsy may be needed to stage the disease accurately.
How NAFLD is treated
There is currently one FDA-approved medication specifically for NASH with fibrosis (resmetirom, brand name Rezdiffra, approved 2024), but the cornerstone of treatment remains metabolic management:
- Weight loss: a 5–10% reduction in body weight reduces liver fat significantly; 10% or more can resolve NASH in a majority of patients. GLP-1 receptor agonists (semaglutide, tirzepatide) are particularly effective and have shown direct benefit in NASH clinical trials
- Diabetes and blood sugar control: improving insulin sensitivity reduces liver fat production
- Lipid management: reducing triglycerides and improving HDL cholesterol support liver health
- Avoidance of alcohol: even moderate alcohol intake accelerates progression in NAFLD
- Dietary modification: Mediterranean-pattern diet has the strongest evidence for liver fat reduction beyond simple caloric restriction
- Vitamin E: may benefit non-diabetic adults with biopsy-proven NASH, but evidence is mixed and high-dose supplementation has risks
Frequently asked questions
Will losing weight actually help my liver?
Yes — weight loss is the single most effective intervention for NAFLD. A loss of 5% of body weight reduces liver fat; 7–10% can resolve inflammation; 10% or more can reduce fibrosis in many patients. GLP-1 medications are particularly effective.
Can I drink alcohol if I have NAFLD?
Current guidelines recommend avoiding alcohol entirely in NAFLD, or at a minimum limiting it to the lowest possible amount. Even light drinking can accelerate liver damage in the context of existing fat accumulation and inflammation.
Is NAFLD reversible?
Simple steatosis (fat without inflammation) is largely reversible with lifestyle change and weight loss. NASH (with inflammation) is often reversible with significant weight loss. Established fibrosis may partially reverse with treatment. Cirrhosis is generally not reversible but can be stabilized.
How do I know how bad my liver is?
Liver function tests and non-invasive fibrosis scores (such as FIB-4) provide an initial assessment. Ultrasound or other imaging can detect fat and structural changes. Liver biopsy is the most definitive test for staging but is reserved for cases where the result would change management.